BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 11205837)

  • 1. Initial P-glycoprotein expression in childhood acute lymphoblastic leukemia: no evidence of prognostic impact in follow-up.
    Kanerva J; Tiirikainen MI; Mäkipernaa A; Riikonen P; Möttönen M; Salmi TT; Krusius T; Saarinen-Pihkala UM
    Pediatr Hematol Oncol; 2001; 18(1):27-36. PubMed ID: 11205837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical significance of P-glycoprotein expression and function for response to induction chemotherapy, relapse rate and overall survival in acute leukemia.
    Wuchter C; Leonid K; Ruppert V; Schrappe M; Büchner T; Schoch C; Haferlach T; Harbott J; Ratei R; Dörken B; Ludwig WD
    Haematologica; 2000 Jul; 85(7):711-21. PubMed ID: 10897123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The combined analysis of P-glycoprotein expression and activity predicts outcome in childhood acute lymphoblastic leukemia.
    De Moerloose B; Swerts K; Benoit Y; Laureys G; Loeys T; Philippé J; Dhooge C
    Pediatr Hematol Oncol; 2003; 20(5):381-91. PubMed ID: 12775536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. P-glycoprotein activity predicts outcome in childhood acute lymphoblastic leukemia.
    Brozek J; Bryl E; Płoszyńska A; Balcerska A; Witkowski JM
    J Pediatr Hematol Oncol; 2009 Jul; 31(7):493-9. PubMed ID: 19564743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of genotype on survival of children with T-cell acute lymphoblastic leukemia treated according to the French protocol FRALLE-93: the effect of TLX3/HOX11L2 gene expression on outcome.
    Ballerini P; Landman-Parker J; Cayuela JM; Asnafi V; Labopin M; Gandemer V; Perel Y; Michel G; Leblanc T; Schmitt C; Fasola S; Hagemejier A; Sigaux F; Auclerc MF; Douay L; Leverger G; Baruchel A
    Haematologica; 2008 Nov; 93(11):1658-65. PubMed ID: 18835836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic impact of age in children and adolescents with acute lymphoblastic leukemia: data from the trials ALL-BFM 86, 90, and 95.
    Möricke A; Zimmermann M; Reiter A; Gadner H; Odenwald E; Harbott J; Ludwig WD; Riehm H; Schrappe M
    Klin Padiatr; 2005; 217(6):310-20. PubMed ID: 16307416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of early treatment response in children with acute lymphoblastic leukemia: a single institution experience in Shanghai, China.
    Tie LJ; Gu LJ; Song DL; Jiang LM; Xue HL; Tang JY; Dong L; Pan C; Chen J; Ye H; Chen J
    Zhongguo Dang Dai Er Ke Za Zhi; 2009 Jan; 11(1):5-9. PubMed ID: 19149913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of karyotypic analysis in children and adults with high-risk acute lymphoblastic leukemia included in the PETHEMA ALL-93 trial.
    Ribera JM; Ortega JJ; Oriol A; Granada I; Hernández-Rivas JM; Parody R; Bethencourt C; Rivas C; Bastida P; del Potro E; González-Valentín ME; Moreno MJ; Besalduch J; Fernández-Calvo J; Tormo M; Arias J; Molinés A; Sanz MA; Maldonado J; Millá F; Feliu E; San Miguel JF;
    Haematologica; 2002 Feb; 87(2):154-66. PubMed ID: 11836166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High white blood cell count at diagnosis of childhood acute lymphoblastic leukaemia: biological background and prognostic impact. Results from the NOPHO ALL-92 and ALL-2000 studies.
    Vaitkevičienė G; Forestier E; Hellebostad M; Heyman M; Jonsson OG; Lähteenmäki PM; Rosthoej S; Söderhäll S; Schmiegelow K;
    Eur J Haematol; 2011 Jan; 86(1):38-46. PubMed ID: 21077959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone marrow recurrence after initial intensive treatment for childhood acute lymphoblastic leukemia.
    Rivera GK; Zhou Y; Hancock ML; Gajjar A; Rubnitz J; Ribeiro RC; Sandlund JT; Hudson M; Relling M; Evans WE; Pui CH
    Cancer; 2005 Jan; 103(2):368-76. PubMed ID: 15599932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia.
    Den Boer ML; Harms DO; Pieters R; Kazemier KM; Gobel U; Körholz D; Graubner U; Haas RJ; Jorch N; Spaar HJ; Kaspers GJ; Kamps WA; Van der Does-Van den Berg A; Van Wering ER; Veerman AJ; Janka-Schaub GE
    J Clin Oncol; 2003 Sep; 21(17):3262-8. PubMed ID: 12947061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prognostic value of the initial response to corticosteroids for children with acute lymphoblastic leukemia].
    Klimza MJ; Sońta-Jakimczyk DJ
    Wiad Lek; 2005; 58(11-12):622-5. PubMed ID: 16594471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prognostic factors for childhood acute non-mature B-lymphoblastic leukemia].
    Jiang H; Gu LJ; Xue HL; Tang JY; Chen J; Pan C; Chen J; Xu C; Dong L; Zhou M
    Zhongguo Dang Dai Er Ke Za Zhi; 2008 Jun; 10(3):290-4. PubMed ID: 18554450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple drug resistance in osteogenic sarcoma: INT0133 from the Children's Oncology Group.
    Schwartz CL; Gorlick R; Teot L; Krailo M; Chen Z; Goorin A; Grier HE; Bernstein ML; Meyers P;
    J Clin Oncol; 2007 May; 25(15):2057-62. PubMed ID: 17513810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significance of the complete clearance of peripheral blasts after 7 days of prednisolone treatment in children with acute lymphoblastic leukemia: the Tokyo Children's Cancer Study Group Study L99-15.
    Manabe A; Ohara A; Hasegawa D; Koh K; Saito T; Kiyokawa N; Kikuchi A; Takahashi H; Ikuta K; Hayashi Y; Hanada R; Tsuchida M;
    Haematologica; 2008 Aug; 93(8):1155-60. PubMed ID: 18519521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early and delayed consolidation chemotherapy significantly improves the outcome of children with intermediate risk acute lymphoblastic leukemia. Final results of the prospective randomized PETHEMA ALL-89 TRIAL.
    Ortega JJ; Ribera JM; Oriol A; Bastida P; González ME; Calvo C; Egurbide I; Hernández Rivas JM; Rivas C; Alcalá A; Besalduch J; Maciá J; Gardella S; Carnero M; Lite JM; Casanova F; Martinez M; Fontanillas M; Feliu E; San Miguel JF;
    Haematologica; 2001 Jun; 86(6):586-95. PubMed ID: 11418367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials.
    Boissel N; Auclerc MF; Lhéritier V; Perel Y; Thomas X; Leblanc T; Rousselot P; Cayuela JM; Gabert J; Fegueux N; Piguet C; Huguet-Rigal F; Berthou C; Boiron JM; Pautas C; Michel G; Fière D; Leverger G; Dombret H; Baruchel A
    J Clin Oncol; 2003 Mar; 21(5):774-80. PubMed ID: 12610173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic factors in childhood acute lymphoblastic leukemia in Japan. Japan Association of Childhood Leukemia Study.
    Horibe K; Hara J; Yagi K; Tawa A; Komada Y; Oda M; Nishimura S; Ishikawa Y; Kudoh T; Ueda K
    Int J Hematol; 2000 Jul; 72(1):61-8. PubMed ID: 10979211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levels of the soluble, 55-kilodalton isoform of tumor necrosis factor receptor in bone marrow are correlated with the clinical outcome of children with acute lymphoblastic leukemia in first recurrence.
    Wu S; Korte A; Gessner R; Henze G; Seeger K
    Cancer; 2003 Aug; 98(3):625-31. PubMed ID: 12879482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute lymphoblastic leukemia in adolescents and young adults in Finland.
    Usvasalo A; Räty R; Knuutila S; Vettenranta K; Harila-Saari A; Jantunen E; Kauppila M; Koistinen P; Parto K; Riikonen P; Salmi TT; Silvennoinen R; Elonen E; Saarinen-Pihkala UM
    Haematologica; 2008 Aug; 93(8):1161-8. PubMed ID: 18556413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.